Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use
Alexander M. Sherwood, Romain Claveau, Rafael Lancelotta, Kristi W. Kaylo, Kelsey Lenoch
ACS Omega December 2, 2020 DOI: 10.1021/acsomega.0c05099 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Process development report Peer reviewed |
|---|---|
| Topics | 5-MeO-DMT DMT |
| Keywords | Yield engineering High-performance liquid chromatography Salt chemistry Active ingredient Impurity Process development Natural product Combinatorial chemistry Organic chemistry Pharmacology Process engineering Alkaloids |
| Citations | 38 |
| Key points | A multigram-scale synthesis of 5-MeO-DMT succinate was achieved with 99.86% purity and 49% net yield, suitable for clinical use. |
Abstract
To support clinical use, a multigram-scale process has been developed to provide 5-MeO-DMT, a psychedelic natural product found in the parotid gland secretions of the toad, Incilius alvarius. Several synthetic routes were initially explored, and the selected process featured an optimized Fischer indole reaction to 5-MeO-DMT freebase in high-yield, from which the 1:1 succinate salt was produced to provide 136 g of crystalline active pharmaceutical ingredient (API) with 99.86% peak area by high-performance liquid chromatography (HPLC) and a net yield of 49%. The report provides in-process monitoring, validated analytical methods, impurity formation and removal, and solid-state characterization of the API essential for subsequent clinical development.
Citations in the library
Cited by 35
- The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) Journal of Neurochemistry February 12, 2022
- 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. Neuropsychopharmacology August 1, 2023
- Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders Molecules April 13, 2022
- 5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk? Psychopharmacology December 11, 2023
- Interaction of psychedelic tryptamine derivatives with a lipid bilayer Chemistry and Physics of Lipids January 7, 2023
and 30 more in the library
Cites 37
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology November 8, 2017
and 32 more in the library